Sagimet Biosciences Holds 2024 Annual Meeting, Elects Directors
Ticker: SGMT · Form: 8-K · Filed: Jun 6, 2024 · CIK: 1400118
Sentiment: neutral
Topics: corporate-governance, annual-meeting, auditor-ratification
TL;DR
Sagimet elected new directors and kept PwC as auditors at their June 4th meeting.
AI Summary
On June 5, 2024, Sagimet Biosciences Inc. filed an 8-K report detailing the results of its 2024 Annual Meeting of Stockholders held on June 4, 2024. The company announced the election of two Class II directors, Dr. Richard S. Levitan and Ms. Sarah E. Empey, to serve until the 2027 annual meeting. Additionally, stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
Why It Matters
The election of directors and ratification of auditors are standard corporate governance procedures that provide transparency and continuity for investors.
Risk Assessment
Risk Level: low — This filing is a routine corporate governance update and does not involve significant financial or operational changes.
Key Players & Entities
- Sagimet Biosciences Inc. (company) — Registrant
- Dr. Richard S. Levitan (person) — Elected Class II Director
- Ms. Sarah E. Empey (person) — Elected Class II Director
- PricewaterhouseCoopers LLP (company) — Independent Registered Public Accounting Firm
- June 5, 2024 (date) — Filing Date
- June 4, 2024 (date) — Annual Meeting Date
- December 31, 2024 (date) — Fiscal Year End
FAQ
Who were elected as Class II directors at the 2024 Annual Meeting of Stockholders?
Dr. Richard S. Levitan and Ms. Sarah E. Empey were elected as Class II directors.
Until what year will the newly elected directors serve?
The newly elected directors will serve until the 2027 annual meeting of stockholders.
What action was taken regarding the company's independent auditor?
The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm.
For which fiscal year was PricewaterhouseCoopers LLP appointed as auditor?
PricewaterhouseCoopers LLP was appointed as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
When was the 2024 Annual Meeting of Stockholders held?
The 2024 Annual Meeting of Stockholders was held on June 4, 2024.
Filing Stats: 698 words · 3 min read · ~2 pages · Grade level 10.7 · Accepted 2024-06-06 06:03:58
Key Financial Figures
- $0.0001 — ich registered Series A Common Stock, $0.0001 par value per share SGMT The Nasdaq G
Filing Documents
- tm2416614d1_8k.htm (8-K) — 36KB
- tm2416614d1_ex99-1.htm (EX-99.1) — 39KB
- tm2416614d1_ex99-1img01.jpg (GRAPHIC) — 4KB
- 0001104659-24-068817.txt ( ) — 261KB
- sgmt-20240605.xsd (EX-101.SCH) — 3KB
- sgmt-20240605_lab.xml (EX-101.LAB) — 33KB
- sgmt-20240605_pre.xml (EX-101.PRE) — 22KB
- tm2416614d1_8k_htm.xml (XML) — 4KB
07
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 5, 2024, Sagimet Biosciences Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). As of April 10, 2024, the record date for the Annual Meeting, there were 30,394,655 outstanding shares of the Company's common stock. The Annual Meeting was conducted virtually, and the following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the Annual Meeting, which are described in detail in the Company's definitive proxy statement for the Annual Meeting, filed with the U.S. Securities and Exchange Commission on April 18, 2024. (a) Proposal 1 - Election of Class I Directors . Each of Paul Hoelscher and Timothy P. Walbert were elected to the Board to serve as Class I directors until the 2027 Annual Meeting of Stockholders and until their successors, if any, are elected or appointed, or their earlier death, resignation, retirement, disqualification or removal, as follows: Name For Withheld Broker Non-Votes Paul Hoelscher 17,078,342 89,926 6,800,117 Timothy P. Walbert 17,078,717 89,551 6,800,117 (b) Proposal 2 - Ratification of Independent Registered Public Accountant . The appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the 2024 fiscal year was ratified, as follows: For Against Abstentions Broker Non-Votes 23,938,535 18,346 11,504 0
01
Item 8.01 Other Events. On June 6, 2024, the Company presented positive data from its FASCINATE-2 Phase 2b clinical trial of denifanstat versus placebo in biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients at the European Association for the Study of the Liver (EASL) Congress 2024 being held in Milan, Italy. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Document 99.1 Press Release of Sagimet Biosciences Inc., dated June 6, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sagimet Biosciences Inc. Date: June 6, 2024 By: /s/ David Happel David Happel Chief Executive Officer